Drugs.com - New Drug Approvals

Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults...

Apr 22, 2025 - 02:14
 0
Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults...
Read More

Tags:

Previous Article

Archer and United Airlines unveil plans for New York air taxi network

Next Article

Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First P...

Related Posts

FDA Grants Isturisa (osilodrostat) Expanded Indication for the Treatment of Endogenous Hypercortisolemia in Patients with Cushing’s Syndrome

FDA Grants Isturisa (osilodrostat) Expanded Indication ...

Apr 23, 2025  0

FDA Approves Qfitlia (fitusiran) to Treat Hemophilia A or B With or Without Inhibitors

FDA Approves Qfitlia (fitusiran) to Treat Hemophilia A ...

Apr 26, 2025  0

ARS Pharmaceuticals Announces FDA Approval of neffy 1 mg (epinephrine nasal spray) for Type I Allergic Reactions in Pediatric Patients

ARS Pharmaceuticals Announces FDA Approval of neffy 1 m...

Apr 26, 2025  0